Next Article in Journal
The Future of Biobanking: What Is Next?
Next Article in Special Issue
Virtual Screening for Potential Inhibitors of Human Hexokinase II for the Development of Anti-Dengue Therapeutics
Previous Article in Journal / Special Issue
Transcriptome Sequencing of the Striped Cucumber Beetle, Acalymma vittatum (F.), Reveals Numerous Sex-Specific Transcripts and Xenobiotic Detoxification Genes
Review

RNF6 as an Oncogene and Potential Therapeutic Target—A Review

1
Students’ Scientific Association of Clinical Genetics, Department of Clinical Genetics, Medical College, University of Rzeszów, Al. Kopisto 2a, 35-959 Rzeszów, Poland
2
Department of Clinical Genetics, Medical College, University of Rzeszów, Al. Kopisto 2a, 35-959 Rzeszów, Poland
*
Author to whom correspondence should be addressed.
Received: 24 August 2020 / Revised: 8 October 2020 / Accepted: 10 November 2020 / Published: 11 November 2020
(This article belongs to the Special Issue Feature Papers 2020)
The RNF6 gene encodes Ring Finger Protein 6 (RNF6), which functions as a ubiquitin ligase. Its functions are not entirely known, but research shows that it is involved in human cancer development. Initially, this gene was considered to be a tumor suppressor. Numerous statistical analyses on cell lines and animals indicate, however, that RNF6 functions as an oncogene, involved in signaling pathways, including SHP1/STAT3, AKT/mTOR, Wnt/β-catenin, or ERα/Bcl-xL. Due to this fact, it has become a potential prognostic factor and therapeutic target. Studies in tumor cells and model organisms using inhibitors such as total saponins from Paris forrestii (TSPf), ellagic acid, or microRNA molecules show the effectiveness of inhibiting RNF6, and through it, the pathways of tumor cell proliferation. The results of the currently available studies are promising, but the function of RNF6 is not fully understood. More research is needed to assess the role of RNF6 and to check the safety and efficacy of inhibitors. View Full-Text
Keywords: molecular targeted therapy; neoplasms; oncogenes; review; RNF6 molecular targeted therapy; neoplasms; oncogenes; review; RNF6
Show Figures

Figure 1

MDPI and ACS Style

Zapolnik, P.; Pyrkosz, A. RNF6 as an Oncogene and Potential Therapeutic Target—A Review. BioTech 2020, 9, 22. https://0-doi-org.brum.beds.ac.uk/10.3390/biotech9040022

AMA Style

Zapolnik P, Pyrkosz A. RNF6 as an Oncogene and Potential Therapeutic Target—A Review. BioTech. 2020; 9(4):22. https://0-doi-org.brum.beds.ac.uk/10.3390/biotech9040022

Chicago/Turabian Style

Zapolnik, Paweł, and Antoni Pyrkosz. 2020. "RNF6 as an Oncogene and Potential Therapeutic Target—A Review" BioTech 9, no. 4: 22. https://0-doi-org.brum.beds.ac.uk/10.3390/biotech9040022

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop